ERBB2 and breast cancer: In the phase II DESTINY-Breast01 study (NCT03248492), ILD of any grade was observed in 15.8% (n = 29) of HER2-positive advanced BC patients who received T-DXd, of whom 2.7% (n = 5) were classified as grade 5.3